Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT00536601
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00534430
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00534469
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00521430
- Locations
- 🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- Drug: busulfanDrug: cyclophosphamideDrug: cyclosporin-ADrug: etoposideDrug: methotrexateDrug: rasburicaseDrug: sirolimusProcedure: allogeneic hematopoietic stem cell transplantationDrug: tacrolimusProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiationDrug: fludarabineDrug: allopurinol
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00513474
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT00506857
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Busulfan and Fludarabine in Patients With AML and MDS
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00502905
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00499889
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Cord Blood Expansion on Mesenchymal Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00498316
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Pentostatin and Targeted Busulfan
- Conditions
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2014-06-05
- Target Recruit Count
- 42
- Registration Number
- NCT00496340
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.